A phase i open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 4, 2015, Pages 777-784

  Jones, Robin L ^a,b   Bendell, Johanna C ^c   Smith, David C ^d   Diefenbach, Konstanze ^e   Lettieri, John ^f   Boix, Oliver ^e   Lockhart, A Craig ^g   O'Bryant, Cindy ^h   Moore, Kathleen N ⁱ  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e BAYER PHARMA AG   (Germany)

^f BAYER CORPORATION   (United States)

^g MO   (United States)

^h UNIVERSITY OF COLORADO CANCER CENTER   (United States)

ⁱ UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Cardiovascular profile; Left ventricular ejection fraction (LVEF); QT QTc interval; Regorafenib

Indexed keywords

REGORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CARDIOTOXIN; NEW DRUG; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR PARAMETERS; CONCENTRATION AT STEADY-STATE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FAINTNESS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE FLUTTER; HOARSENESS; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QT INTERVAL; QTC INTERVAL; SEIZURE; SMALL INTESTINE PERFORATION; SOLID TUMOR; STEADY STATE; SUDDEN CARDIAC DEATH; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; AGED; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; DRUG ERUPTION; ELECTROCARDIOGRAPHY; HEART STROKE VOLUME; HEART VENTRICLE; METABOLISM; MIDDLE AGED; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEOPLASMS; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; ANTINEOPLASTIC AGENTS; CARDIOTOXINS; CARDIOVASCULAR DISEASES; DIARRHEA; DRUG ERUPTIONS; DRUGS, INVESTIGATIONAL; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MUCOSITIS; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME;

EID: 84942192960     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2827-3     Document Type: Article

References (15)

1. Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245-255
2. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
3. Fabian MA, Biggs WH 3rd, Treiber DK et al (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336
4. International Conference on Harmonisation (2005) Guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Fed Regist 70:61134-61135
5. Strumberg D, Scheulen ME, Schultheis B et al (2012) Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 106:1722-1727
6. Mross K, Frost A, Steinbild S et al (2012) A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658-2667
7. Khakoo AY, Kassiotis CM, Tannir N et al (2008) Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112:2500-2508
8. Machiels JP, Bletard N, Pirenne P, Jacquet L, Bonbled F, Duck L (2008) Acute cardiac failure after sunitinib. Ann Oncol 19:597-599
9. Schmidinger M, Zielinski CC, Vogl UM et al (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204-5212
10. Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019
11. Telli ML, Witteles RM, Fisher GA, Srinivas S (2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19:1613-1618
12. Di Lorenzo G, Autorino R, Bruni G et al (2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20:1535-1542
13. Tolcher AW, Appleman LJ, Shapiro GI et al (2011) A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 67:751-764
14. Heath EI, Infante J, Lewis LD et al (2013) A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemother Pharmacol 71:565-573
15. Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK (2014) QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 112:296-305